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Abstract 
 
The limits of TDF (time, dose, and fractionation) and linear quadratic models have been known 
for a long time. Medical physicists and physicians are required to provide fast and reliable 
interpretations regarding the delivered doses or any future prescriptions relating to treatment changes. 
We therefore propose a calculation interface under the GNU license to be used for equivalent doses, 
biological doses, and normal tumor complication probability (Lyman model). The methodology used 
draws from several sources: the linear-quadratic-linear model of Astrahan, the repopulation effects of 
Dale, and the prediction of multi-fractionated treatments of Thames. The results are obtained from an 
algorithm that minimizes an ad-hoc cost function, and then compared to the equivalent dose computed 
using standard calculators in seven French radiotherapy centers.  
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Nomenclature 
 
       fitting parameters of the linear quadratic 
model of cell survival (Gy² et Gy) 
  cost function to minimize by the 
algorithm 
      adjustment parameter of the occurrence 
model of cancer radio-induced (Gy-1) 
   number of day-offs 
     Heaviside function 
   LQ model correction taking account the 
poly-fractionation 
 
 
 parameter of the LQL model 
           occurrences probability of radio 
induced cancer (%) 
  parameter adjustment necessary to take 
into account the poly-fractionation in the model 
LQ (hours-1) 
  fraction number and slope factor of the 
NTCP model 
     biological equivalent dose (Gy)   nombre de fraction 
D physical dose (Gy) NTCP complications rate of post radiation (%) 
dt dose per fraction from which the curve 
of cell survival becomes linear (Gy) 
      parameter related to the occurrence of 
radiation-induced cancers (Gy-1) 
      proliferation dose (Gy/day) 
   duration between two irradiations 
(heures) 
        equivalent doses for the treatment 1 
and 2 (Gy) 
  overall time (day) 
     equivalent dose for a 2 Gy/Fraction 
treatment (Gy) 
TD50 dose at which there is a 50% complication 
(Gy) 
EUD Equivalent uniform Dose (Gy) 
   time at which repopulation begins after 
start of treatment (day) 
      EUD for an equivalent dose related to a 
reference of 2 Gy per fraction 
     potential doubling time (day) 
Tstop       days off during the treatment 
   boundary used in the NCTP calculus (Gy) 
 
  
I. Introduction: Problems of the biologically equivalent dose 
 
It has long been known that radiation biology plays an important role and is necessary for 
radiotherapy treatments. The radiation effects on normal and malignant tissues after exposure range 
from a femtosecond to months and years thereafter [1,2]. Therefore, to optimize treatment, it is crucial 
to explain and understand these mechanisms [3-5]. Providing a conceptual basis for radiotherapy and 
identifying the mechanisms and processes that underlie the tumor and normal tissue responses to 
irradiation can help to explain the observed phenomena [6]. Examples include understanding hypoxia, 
reoxygenation, tumor cell repopulation, or the mechanisms of repair of DNA damage [3,7,8]. The 
different biological effects of radiation should be divided into several phases: the physical phase 
(interaction between charged particles and tissue atoms), chemical phase (the period during which the 
damaged atoms and molecules react with other cellular components in rapid chemical reactions), and 
biological phase (impact of the generated lesions on the biological tissue [4]). The following section 
describes the models most often used in radiotherapy. These are simplistic models that actual 
treatments are based, and that are validated and approved [9-12].  
1. Reference models 
 
Numerous models exist to evaluate the biological equivalent dose, but the two most common are 
the nominal standard dose (NSD [13]) and linear quadratic (LQ [9]) models. The NSD uses the power 
law described in equation 1 below (     is the tolerance dose of the tissue, NSD is a constant, n and t 
   , N the number of fractions, and T the overall treatment time). However, this model has been 
often criticized [14]. In short, some researchers consider and have even shown that the NSD formula is 
not a valid description for all tumors and normal tissues; instead, they maintain that the model 
incorrectly describes the effects of fraction number and treatment duration. 
          
           Eq 1 
The LQ model is most frequently used in the radiotherapy units. It allows the equivalent dose to be 
easily evaluated for different fractionations. This concept involves the 
 
 
 ratio, as shown in equation 2 
below (D is the total dose for a fraction size of d gray). 
       
  
 
 
  
 
 
         Eq 2 
     is the dose obtained using a 2Gy fraction dose, which is biologically equivalent to the total dose 
D given with a fraction dose of d gray. The values of      may be added in separate parts in the 
treatment plan. This formula may be adapted to fraction doses other than 2Gy. 
2. Limitations of the LQ model 
 
The LQ model is frequently used for modeling the effects of radiotherapy at low and medium 
doses per fraction for which it appears to fit clinical data reasonably well. The main disadvantage of 
the LQ approach is that the overall time factor is not taken into account, because in radiotherapy it is 
regarded to be more complex than previously supposed [3]. It is indeed very difficult to include this 
parameter in the LQ equation. However, a technique may be used to integrate a penalty term in 
Equation 2. Thus, for Tstop days off treatment, the dose recovered would be Tstop.Dprol, where Dprol  is the 
proliferation factor (in Gy/day; for example, 0.22 for laryngeal edema or 0.15 for rectosigmoid 
complications). This methodology is essentially validated for discontinuation during treatment. As a 
general rule, the main limitations of using the LQ model are linked to repopulation  (LQ doesn’t take 
into account the dose protraction), bi-fractionated treatments and high-dose fractions (continuously 
bending survival curve versus linear behavior observed at least in some cell lines). Other more 
sophisticated models, however, take into account these weaknesses. We will later see that the LQ 
model requires further theoretical investigation, especially in terms of the biologically effective dose 
(BED). 
Given the difficulty of computing the BED, we conducted a study in seven radiotherapy centers in 
France: CHD Castelluccio (Ajaccio; two classical calculators used), Centre de Cancérologie du Grand 
Montpellier (Montpellier), CRLCC Paul Lamarque (Montpellier), Clinique Saint-Pierre (Perpignan), 
Centre de la République (Clermont Ferrand), CHU of Grenoble, and CHU of Nîmes. A questionnaire 
was sent to medical physicists working at these centers, with the aim of comparing the results of 
equivalence (for standard radiotherapy planning). Table 1 presents the results of this survey, which 
indicate that not all of the operators obtained the same results. The 95 % confidence interval was often 
very large. Moreover, the relative standard deviation (also known as the dispersion coefficient) was 
frequently greater than 5% (13 times out of 24). This dispersion was larger in the case of target 
volumes; the maximal volume (close to 40%) was related to high doses per fraction with a gap 
between two radiotherapy cycles. In Table 1, it is evident that all of the users did not estimate dose 
equivalence in the same manner. Only for a dose per fraction approaching 2Gy and standard overall 
time were the results equivalent. Note that in the multi-fractionated treatments, only 50% of the 
centers were able to give an equivalent dose, as this kind of treatment was not computable.  
Treatements   Organs at risk Target volumes 
10x3Gy 
  Spinal cord Prostate (metastasis) 
Median 37.50 36.65 
average ± 95% CI 37.8 ± 1.2  36.6 ± 1.9 
stand dev 1.71 / 4.5% 2.87 / 7.8% 
10x3Gy 
  Spinal cord Breast (metastasis) 
median 37.50 35.57 
average ± 95% CI 37.8 ± 1.2 35.97 ± 1.4 
stand dev 1.71 / 4.5% 2.06 / 5.7% 
1x8Gy 
  Spinal cord Prostate (metastasis) 
median 20.00 14.90 
average ± 95% CI 19.1 ± 2.3 15.9 ± 3.2 
stand dev 3.38 / 17.7% 4.72 / 29.6% 
10x3Gy 
  Brain Breast (metastasis) 
median 37.50 35.57 
average ± 95% CI 37.5 ± 0.9 35.9 ± 1.4 
stand dev 1.26 / 3.4% 2.03 / 5.6% 
1x8Gy                         
(1 month gap time) 
1x8Gy 
  Spinal cord Prostate (metastasis) 
median 33.30 21.50 
average ± 95% CI 33.6 ± 4.0 24.04 ± 6.8 
stand dev 5.78 / 17.2% 9.76 / 40.6% 
5x4Gy 
  Pericardium Lung (metastasis) 
median 30.90 27.07 
average ± 95% CI 33.7 ± 5.9 28.9 ± 3.6 
stand dev 8.47 / 25.1% 5.14 / 17.8% 
20x2Gy (1 week 
gap time) 10x2Gy 
  Oral mucosa Oropharynx 
median 57.95 57.95 
average ± 95% CI 58.1 ± 0.5 57.6 ± 1.9 
stand dev 0.66 / 1.14% 2.76 / 4.8% 
22x1.8Gy (bi-
fractionated) 
  Oral mucosa Oropharynx 
median 41.95 41.70 
average ± 95% CI 41.0 ± 1.6 41.7 ± 2.2 
stand dev 2.32 / 5.6% 3.12 / 7.5% 
25x1.8Gy then 
15x2Gy 
  Rectum Prostate 
median 72.58 72.75 
average ± 95% CI 72.6 ± 0.4 72.6 ± 0.7 
stand dev 0.54 / 0.7% 1.00 / 1.37% 
20x2.5Gy (4 
fraction/week) 
  Lung Breast 
median 55.58 53.50 
average ± 95% CI 55.0 ± 1.1 53.5 ± 1.2 
stand dev 1.59 / 2.9% 1.71 / 3.2% 
4x4.5Gy (2 week 
gap time) 4x4Gy 
  Optic chiasma Glioblastoma 
median 50.25 42.15 
average ± 95% CI 49.9 ± 2.7 43.1 ± 2.8 
stand dev 3.96 / 7.9% 4.07 / 9.4% 
28x1.8Gy (1 week 
gap time) 
  Skin (early) Breast 
median 46.65 46.36 
average ± 95% CI 46.7 ± 0.6 46.5 ± 0.8 
stand dev 0.90 / 1.9% 1.13 / 2.4% 
Table 1: Methodologies for computing the equivalent dose used in eight clinical calculators from seven radiotherapy 
centers. The median dose, average dose, and standard deviation are given in Gy. For the standard deviation, absolute 
and relative modes (/average) were used. Bold font is used to represent values >5%  
 
The numbers of centers included in this study was low, and there was no consensus among the 
centers in terms of their methods for computing the doses. If we look more closely, the biological 
equivalent dose was the only process that was calculated using non-official software. All of the other 
steps in treatment planning followed an official protocol. It is thus legitimate to ask why centers use 
in-vivo dosimeters or try to achieve a global error of 2% throughout treatment, if the prospective 
calculation of the equivalent dose (and prescription) is greater than 20%. In order to address the 
question of responsibility, the following section of this article is targeted at medical physicists, 
knowing that the prescriber is the physician. In case of equivalent computations, the optimal operation 
would be for the technical work to be performed by the physicist and validations by the physician 
(while taking into account the clinical scenario). This methodology allows for a double checking of the 
calculation results. 
The next section describes the theoretical methodology that we propose to compute the BED. 
II. Materials and methods: the developed models 
 
The BED (introduced by Fowler [9]) is a mathematical concept used to illustrate the biological 
effects observed after irradiation. In addition to being easily computable (BED = physical dose x 
relative efficiency), this notion is interesting because two irradiations with the same BED generate the 
same radiobiological effects. For this reason, it is easy to compare treatments with different doses, 
fractionations, and overall times. The following section introduces the BED-based models that we 
advocate as well as the rules and guidelines for using the LQL_equiv software. 
1. Target volume models 
 
Let us examine two different treatment cases separately. The first involves treatments with a high-
dose fraction (one treatment per day, the fraction size d is greater than the dt limit; [15]), which 
requires a linear quadratic linear (LQL) model. The second case relates to other treatments (d < dt), 
where the LQ model is applicable to daily multi-fractionation [16]. 
a. The d > dt  case 
 
When the dose per fraction (d) is greater than the LQL threshold (dt ~ 2   ⁄ ), the BED is 
computed using Equation 3 below (one fraction permitted per day). This template regroups Astrahan’s 
high-dose model [17] and Dale’s repopulation model [18] (n is the number of fraction,      the 
Heaviside function, 
 
 
 the parameter of the LQL model and      the potential doubling time in day). 
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         Eq 3 
The second term used in this equation is useful only when the overall time T is greater than the Tk 
value (kick-off time). If this threshold is not achieved, the tumor is considered to be non-proliferative 
(early hypoxia). 
 
b. The d ≤ dt  case 
 
When the fraction dose is low, it is possible to use the standard BED equations while considering 
one or more fractions per day (Equation 4). This methodology follows the model of Thames [19], who 
introduces the repair factor Hm related to the amount of unrepaired damage (Equation 5).  If the inter-
fraction interval is reduced below the full repair interval (between 6 hours and 1 day), the overall 
damage from the whole treatment is increased because the repair of damage due to one radiation dose 
may not be complete before the next fraction is given (   is LQ model correction taking account the 
poly-fractionation, m the number of fraction per day,   the incomplete repair and   the parameter 
adjustment necessary to take into account the poly-fractionation in the model LQ in hours
-1
). 
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Note that in the case of mono-fractionation, the Hm factor is null. These equations only relate to the 
target volume calculation. For the organs at risk, the kick-off time is not relevant, meaning that it is 
necessary to use a repopulation-specific approach.  
2. Models for organs at risk  
 
As in the precedent section on target volumes, this section similarly separates high and low doses 
per fraction. The BED formulae are almost equivalent to the target volume model; only the terms 
relating to the lack of dose by proliferation are modified. 
a. The d > dt  case 
 
To understand this methodology, it is necessary to consult Van Dyk’s law [20]. The kick-off time 
is no longer considered, with the recovered dose (     
     
      
 in Gy/day) instead being added. The 
global model is described in Equation 6 below. 
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       )            Eq 6 
 
 
b. The d ≤ dt  case 
 
In the case of low doses per fraction, the methodology is similar to the target volume model: the 
   parameter (Equation 5) is nonetheless required, which allows us to take into account more than 
one fraction per day. As seen in the Equation 7 below, the recovered dose is used as in the previous 
case. 
        (         
 
  ⁄
)             Eq 7 
 
3. Computational methods for the equivalent dose  
 
The standard models used for the equivalent dose as based on the LQ approach are easily 
exploitable. The main formulation of the model (Equation 2) can be obtained by considering the 
general formula described in the Equation 8 as follows.  
      
   ⁄     
   ⁄     
        Eq 8 
This equation may be validated using BED methodology. Considering the BED of two treatments to 
be equal, it appears that a simple relation links the two overall doses,            and           . 
The detail of this procedure is shown in the Equation 9 below. 
           (   
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)    Eq 9 
In the case of more sophisticated BED formulations, it is not easy to determine a simple formula 
linking the          doses, as recovery and repopulation significantly complicate the computational 
principle. Most of the existing software that uses the overall time correction does not calculate the 
equivalent dose; instead, it only provides the BED for the chosen treatments. In clinical use, it is more 
valuable for the physician or physicist to work with the equivalent dose in standard fractionation. In 
this context, the methodology used in the LQL_Equiv software is based on an innovative algorithm, 
which allows a cost function extremum to be determined based on BED modeling. To explain this 
methodology, it is necessary to consider two irradiations (Indices 1 and 2), which are defined by a 
fraction number (n), dose per fraction (d), and days of discontinuation (ja). The corresponding BED is 
noted as BED1 (n1,d1,ja1) and BED2 (n2,d2,ja2), while the cost function f is defined in Equation 10 as 
follows. 
                        |                                |  Eq 10 
In clinical use, it is desirable to compare a radiotherapy trial with one that is performed in a 
conventional manner (generally with 2 Gy per fraction without interruption). This concept of a 
reference dose simplifies the issue, as it is thus possible to dispense with the days off treatment and 
multi-fractionation per day in relation to the reference treatment. The following example concerns a 
tumor case with a dose per fraction less than dt (second part of the target volume model), while the 
cost function, f, is given in Equation 11. Concerning the three other cases examined in previous 
sections, a similar relationship is found. 
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       | Eq 11 
The global treatment duration can be seen to be directly associated with the fraction number and days 
off during radiotherapy. Following Equation 11, the 2Gy-per-fraction equivalent dose (EQD2) for 
standard treatment with the characteristics        is given by the algorithm shown in Equation 12. 
{
              (             )    
         
      Eq 12 
All of the results obtained in this section were implemented using a Matlab® standalone application 
known as LQL-equiv. The characteristics of this software, its limitations, and guidelines for its use are 
discussed in the following section. 
III. Results: LQL_Equiv software 
 
The LQL_Equiv software was developed in collaboration by the CHD Castelluccio radiotherapy 
unit in Ajaccio and the University of Corsica. It is a free software released under the GNU license. The 
source codes, executable file, help files, and license terms are available at http://cyril-voyant.univ-
corse.fr/LQL-Equiv_a34.html. Before installing this software, it is advisable to refer to the installation 
guide and to download and execute Matlab Component Runtime (MCR 32 bits, version 7.15 or later). 
This latter step is necessary since the application was programmed using the GUI Matlab® software 
(32 bits, v. 7.12) and deployed with the Matlab Compiler® (v. 4.12), which use MCR (a standalone set 
of shared libraries enabling the execution of Matlab® applications on a computer without an installed 
version of Matlab®). Users of the LQL_Equiv software are advised to provide us with comments on 
the software, its libraries (biological parameters for each organ or tumor type), or any bugs so as to 
allow us to develop the software. Note that the application requires Microsoft Windows® (the 
resolution and colors are for Vista or later versions).  
1. Software  
 
The graphical interface of the LQL_Equiv software software is presented in the Figure 1, divided 
into five sections: demographical zone, tissue choice (organs at risk and target volumes), reference 
zone (characteristics for computing the equivalent dose), treatment planning zone (three juxtaposed 
and independent treatments), and finally, the equivalent dose under the reference conditions. Prior to 
using the software, it is important to understand that repopulation or a high dose per fraction can 
considerably alter the standard equivalent results. Therefore, it is recommended for each user to verify 
the results obtained and validate them during an initial test phase. The results must be consistent with 
routine procedures as well as the data in the literature. The detail of the instructions allowing to use the 
software is available in the annex part. 
 
Figure 1: Graphical interface for the LQL_Equiv software 
 
The ideal scenario would be to compare these results with other software and obtain a mean score 
for the two outputs or for the outputs that minimize the physical dose. We recommend using this 
software as a secondary BED calculator. It aims to provide assistance, but cannot be used as a 
substitute for routine calculations made by a professional. The creators of the LQL_Equiv software 
cannot be held responsible for any errors caused by the misuse of the results obtained. 
2. Comparison with standard models 
 
This section compares the results of the LQL_Equiv software with the available clinical models. 
However,, it is important to note that all of the parameters used for calculating the equivalence are 
available on the graphical interface. Using Matlab™ and the downloadable source codes, it is easy to 
modify or complete these parameters. It is also possible to contact the software authors to assist in 
developing the software. LQL_Equiv is in direct competition with TDF Plan developed by Eye 
Physics LLC, which proposes a multitude of parameters. However, the software is dedicated to the 
calculation of BED and is not really consistent with the reference equivalent dose. Moreover, we 
aimed to develop ergonomic software with minimum of adjustable parameters, which ultimately 
complicate the interpretation of the output. These two approaches are nevertheless complementary; for 
more information about the different models used, refer to the TDF Plan website 
(http://www.eyephysics.com/tdf/Index.htm). Table 2 presents a comparison between outputs of the 
standard calculation models described in section II (LQ without proliferation and   ⁄  =10 for oral 
mucosa and 2 for others) and the LQL-equiv software. The difference between the two approaches is 
substantial. The overall time effect and unusual doses per fraction result in completely different 
outputs. The maximum difference is close to 25%; this value is linked to the cell repopulation of 
prostate cancer. In this case, the non-specific methods are certainly not usable.  
Treatements   Organs at risk Target volums 
10x3Gy 
  Spinal cord Prostate (metastasis) 
classical output (Gy) 37.5  37.5 
LQL-equiv output (Gy) 37.5 36 
difference (Gy / %) -0 / -0% -1.5 / -4% 
10x3Gy 
  Spinal cord Breast (metastasis) 
classical output (Gy) 37.5 37.5 
LQL-equiv output (Gy) 37.5 38.2 
difference (Gy / %) -0 / -0% 0.7 / 1.9% 
1x8Gy 
  Spinal cord Prostate (metastasis) 
classical output (Gy) 20 20 
LQL-equiv output (Gy) 16 16.8 
difference (Gy / %) -4 / -20% -3.2 / -16% 
10x3Gy 
  Brain Breast (metastasis) 
classical output (Gy) 37.5 37.5 
LQL-equiv output (Gy) 43.5 38.2 
difference (Gy / %) 6 / 16% 0.7 / 1.9% 
1x8Gy                         
(1 month gap 
  Spinal cord Prostate (metastasis) 
classical output (Gy)) 40 40 
time) 1x8Gy LQL-equiv output (Gy) 32 33.3 
difference (Gy / %) -8 / -4.63% -6.7 / 16.7% 
5x4Gy 
  Pericardium Lung (metastasis) 
classical output (Gy) 30 30 
LQL-equiv output (Gy) 37.5 23.3 
difference (Gy / %) 7.5 / 25% -6.7 / -22.3% 
20x2Gy (1 week 
gap time) 10x2Gy 
  Oral mucosa Oropharynx 
classical output (Gy) 60 60 
LQL-equiv output (Gy) 54.4 53 
difference (Gy / %) -5.6 / -9.3% -7 / -11.7% 
22x1.8Gy (bi-
fractionated) 
  Oral mucosa Oropharynx 
classical output (Gy) 38.9 38.9 
LQL-equiv output (Gy) 45 36 
difference (Gy / %) 6.1 / 15.7% -2.9 /-7.4% 
25x1.8Gy then 
15x2Gy 
  Rectum Prostate 
classical output (Gy) 72.7 72.7 
LQL-equiv output (Gy) 71 73 
difference (Gy / %) -1.7 / -2.3% 0.3 / 0.4% 
20x2.5Gy (4 
fraction/week) 
  Lung Breast 
classical output (Gy) 56.2 56.2 
LQL-equiv output (Gy) 62.9 56.8 
difference (Gy / %) 6.7 / 11.9% 0.2 / 0.3% 
4x4.5Gy (2 week 
gap time) 4x4Gy 
  Optic chiasma Glioblastoma 
classical output (Gy) 53.2 53.2 
LQL-equiv output (Gy) 42.8 47.4 
difference (Gy / %) -10.4 / -19.5% -5.8 / -10.9% 
28x1.8Gy (1 week 
gap time) 
  Skin (early) Breast 
classical output (Gy) 47.9 47.9 
LQL-equiv output (Gy) 47.6 42.3 
difference (Gy / %) -0.3 / 0.6% -5.6 / -11.7% 
Table 2 : Comparison between the outputs of the LQL_Equiv and standard calculation models (LQ without proliferation 
and with   ⁄  =10 for oral mucosa and 2 for others). Bold font is used to show differences >5%. 
 
In addition, for the BED and equivalent calculations, the LQL_Equiv software allows two other 
parameters to be obtained, which may be useful in clinical practice: the normal tumor complication 
probability (NTCP; [22]) and the ratio of radiation-induced cancer after irradiation. 
3. Others elements computed by the software 
 
In the LQL_Equiv software, the bottom the interface is dedicated to the calculation of the NTCP 
and ratio of radiation-induced cancer. For the first parameter, the formula for its computation (only for 
normal tissues) is based on the Lyman model [22] as presented in the Equation 12 below (TD50 is the 
dose at which there is a 50% complication in Gy,   the boundary used in the NCTP calculus in Gy and 
m the slope factor). To use this formula, it is necessary to first compute the EUD (Niemerko [21]). 
However, in practice, this quantity is not feasible. It is instead possible to use the equivalent dose 
related to a reference dose of 2 Gy per fraction (        
    . However, the NTCP formalism is 
valid for 2±0.2 Gy/fraction. Moreover, the DVH must be used, in which case the equivalent dose 
refers to the average dose for the parallel organs or the maximal dose (D5%) for the serial organs. 
{
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      Eq 13 
 
The second add-on in the software concerns the estimation of radiation-induced cancer. The theory 
used was developed by the United Nations Scientific Committee on the Effects of Atomic Radiation 
(UNSCEAR; http://www.unscear.org/unscear/fr/publications.html). The different meta-analyses of 
previous radiological incidents are used in this model. The ratio of radiation-induced cancer (in %) 
relating to normal tissue is provided in Equation 14 as follows (      is the adjustment parameter of 
the occurrence model of cancer radio-induced in Gy-1,       the UNSCEAR probability and  
    the 
equivalent dose for a 2 Gy/Fraction treatment in Gy).  
                   
            
   
     Eq 14 
Note that methods used to compute NTCP and Kincidence are simplified; it is evident that interested 
readers must identify more specialized documents. These parameters are given as additional 
information. 
IV. Conclusion 
 
In this article, we have exposed the compiling results of various published LQ model 
modifications, which have been modified to be better suited for specialized radiotherapy techniques 
such as hypo- or hyperfractionation. The LQ model was modified to take into account multi-
fractionation, repopulation, high-dose fractions, and overall time. Moreover, we propose a software 
program (LQL_equiv), integrating all of these concepts regarding the main organs at risk or target 
volumes. Moreover, this free and easy-to-use software allows the NTCP to be calculated. Finally, this 
software permits the obtained results to be compared and validated against other “homemade” models, 
with the purpose of harmonizing practices in interested centers. However, it is essential to don’t 
consider models as “general biological rules”, parameters and outputs uncertainties can be very large; 
this phenomenon is related to the number of regression parameters (parsimony principle) and to the 
data snooping (e.g. failure to adjust existing statistical models when applying them to new datasets). 
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VI. Annex 1: Instructions for use 
 
The number of modifiable parameters in the LQL_Equiv software is minimal, while the items 
required to complete a dose equivalent calculation are limited. Only the white boxes can be modified.  
The upper left part of the interface is dedicated to patient demography (identity and pathology) 
and operator traceability. These parameters are not essential for initiating the calculation. Below this, 
the reference dose per fraction should be provided; by default, the dose is 2 Gy/fraction.  
In the top-right of the interface, there are two dropdown menus related to the organs at risk and 
target volumes chosen by the operator to obtain the equivalent dose. Once these steps are completed, it 
is necessary to define the desired treatment plans. Only three plans are proposed, but the software is 
able to test more by integrating the overall results in a single treatment plan, such as the EQ1 (dose, 
days off, and number of fractions must be adjusted). The overall time must be verified or else there 
may be some imprecision in the final calculation. A null number of fractions or doses results in 
cancelling the calculation of the equivalent dose (the duration of the sequence does not contribute to 
the final output).  
After selecting the treatment plan and clicking on the calculation button, the BED and equivalent 
doses are given. The page may be printed, or otherwise, there is the digital archiving solution based on 
the Windows™ print screen button.  
When taking into account the days off, the weekend should not be considered; only 
discontinuations that occur during weekdays should be included. Beyond 20 days off from treatment, 
the algorithms are no longer valid. In the first approximation, the side of caution indicates that healthy 
tissues do not recover during the gap time. For the second cycle of radiotherapy that occurs a long 
time after the first, we must be vigilant with regard to the treated organs. In the case of the skin, for 
example, we may consider a duration of 2 to 5 years to be sufficient to negate any effects from the 
previous treatment (this is, however, invalid if the effects are already visible at the time of irradiation), 
while for the spinal cord, it must be considered, where possible, that there exists a dose memory, with 
the effects of gray radiation always being present. In this regard, the software takes into account that 
certain organs, such as spinal cord, have a low Drec in order to limit the consequences to the most 
critical organs. Moreover, it is necessary to consider all of the treatment phases if a dose equivalent is 
required for the second stage of a prostate disease. In this case, the first phase of the treatment must be 
considered, or otherwise, the kick-off time will not be correctly taken into account.  
To avoid the dose overestimation, we recommend first calculating the dose equivalent for the 
organ, i.e., the limiting factor, and then estimating the fractionation effect on the target volume.  
For organs at risk, it is possible to use the nominal dose. Thus, in the case of the pelvis, for the 
first 45 Gy given in 25 fractions, the dose received by the rectum may be considered equal to 45 Gy. 
However, in order to optimize the methodology, it seems more reasonable to utilize a more detailed 
analysis. If the validation criterion is D30, the software should be completed according to the dose per 
fraction and number of fractions for the dose received by 30% of the rectum. It is also possible to use 
the average dose for parallel organs, maximal dose for serial organs, or simply the equivalent uniform 
dose (EUD) [21]. Another example illustrating the difference between the critical dose and nominal 
standard dose is based on spinal irradiation. If doses of 30 Gy in 10 fractions are delivered, this does 
not necessary mean that the spinal cord has received the entire dose. Dose volume histogram (DVH) 
analysis allows us to observe that the spinal cord received 32 Gy after the 10 fractions, which means 
that the equivalent dose is 10 fractions of 3.2 Gy, which significantly changes the results.  
Furthermore, it should be added that in this software, as is often the case, the time between two 
irradiations in bi-fractionated radiotherapy must be greater than 6 hours.  
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